Medivance Inc.
This article was originally published in Start Up
Executive Summary
Medivance Inc. aims to improve on the safe, but cumbersome surface methods of applying hypothermic therapy to minimize ischemic damage. Its Arctic Sun Temperature management system is designed to be safer to use than more invasive methods of temperature control, and faster-acting than traditional surface approaches.
You may also be interested in...
Is Therapeutic Hypothermia Finally Heating Up?
Therapeutic hypothermia companies have largely been disappointing for investors who poured in -- and lost -- fortunes investing in promising cooling technologies. But while many first-generation start-ups no longer exist, the technologies they developed live on within the large corporations that paid pennies on the dollars to acquire them. Although the pioneers in the field failed to meet their objectives, there is reason for hope. Their corporate acquirers have continued to move the technology down the field. The end zone may not be in sight, yet, but advancement is slow and steady. Meanwhile, medical societies including the American Heart Association have issued guidelines on how hospitals should employ therapeutic hypothermia in treating patients. Similarly, some decision makers - including the City of New York - are requiring patients be taken to facilities that offer cooling treatments, giving the field the legitimacy it lacked for so long. Finally, innovation is beginning to take root again as new start-ups develop a next generation of therapeutic hypothermia devices. Taken together, these developments suggest that patient temperature management may arrive someday soon.
Philips buys Innercool: The Ice Age Cometh
As part of a bid to connect the dots between its own product offerings, Philips Healthcare acquired InnerCool Therapies, maker of surface and endovascular cooling devices for the management of cardiac patients. InnerCool fits into the company's broader "care cycle" strategy, the point of which is to provide a continuum of care to patients in the diseases Philips serves. Specifically, Philips' strategy is to connect diverse care settings to its product markets, in this case, cardiac resuscitation. The combination marks a change in how sudden cardiac arrest is regarded, from an isolated episode focused on a stopped heart to a larger strategy of patient management.
SPAC Merger Opens Door for Alsius
Alsius Corp., manufacturer of a device to lower body temperature, founds its way to the public market by merging with Ithaka Acquisition Corp., a special purpose acquisition company.